More than 16 years ago human interferon-β-1b (IFN-β-1β) was shown to be effective in the treatment of the relapsing-remitting form of multiple sclerosis (MS). Over time, IFN-β has been demonstrated to be both a safe and effective treatment. However, the mechanism of action of IFN-β in MS remains unknown. To better understand the mechanism of action of IFN-β, considerable effort has been made in transcriptional profiling of peripheral blood mononuclear cells collected from MS patients. IFN-β is known to induce a large number of genes that play an important role in regulating responses to viral infection, immune modulation, and cell proliferation. Identifying differentially induced genes that are linked to the beneficial effects observed during treatment is under active investigation. IFN biomarkers in MS patients have been proposed but have not been clearly confirmed in independent studies or consistently correlated with clinical measures of disease progression. Organizing single genes or gene signatures grouped according to molecular mechanisms meaningful in MS may help to link IFN activity measurements to clinical outcomes. In this review, IFN activity measurements will be discussed with a specific emphasis on what is known about differential gene expression and treatment effects in MS.
Get full access to this article
View all access options for this article.
References
1.
AchironA, GurevichM, FriedmanN, KaminskiN, MandelM. 2004. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol, 55:410–417.
2.
AgrawalSM, YongWW. 2007. Immunopathogenesis of MS. Int Rev Neurobiol, 79:99–126.
3.
ArnasonBGW, DayalA, QuZX, JensenM, GençK, RederAT. 1996. Mechanisms of action of interferon beta in multiple sclerosis. Semin Immunopathol, 18:125–148.
4.
AxtellRC, de JongBA, BonifaceK, van der VoortL, BhatR, De SarnoP, NavesR, HanM, ZhongF, CastellanosJG, MairR, ChristakosA, KolkowitzI, KatzL, KillesteinJ, PolmanCH, de Waal MalefytR, SteinmanL, RamanC. 2010. T helper type I and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med, 16:406–412.
5.
BaranziniSE, MousaviP, RioJ, CaillierSJ, StillmanA, VillosladaP, WyattMM, ComabellaM, GrellerLD, SomogyiR, MontalbanX, OksenbergJR. 2005. Transcription-based prediction of response to IFN-β using supervised computational methods. PLoS Biol, 3:E2.
6.
BauchA, Superti-FurgaG. 2006. Charting protein complexes, signaling pathways, and networks in the immune system. Immunol Rev, 210:187–207.
7.
BildA, FebboPG. 2005. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc Natl Acad Sci U S A, 102:15278–15279.
8.
BrazhnikP, de la FuenteA, MendesP. 2002. Gene networks: how to put the function in genomics Trends Biotech, 20:467–472.
9.
ByskoshPV, RederAT. 1996. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler, 1:262–269.
10.
CalabresiPA, TranquillR, DambrosiaJM, StoneL, MaloniH, BashCN, FrankJ, McFarlandHF. 1997. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. J Neuroimmunol, 41:669–674.
11.
CalvanES, XiaoW, RichardsDR, FelcianoRM, BakerHV, ChoRJ, ChenRO, BrownsteinHB, CobbJP, TschoekeSK, Miller-GrazianoLC, MoldaweL, MindrinosMN, DavisRW, TompkinsRG, LowrySF. 2005. A network-based analysis of systemic inflammation in humans. Nature, 437:1032–1037.
ComabellaM, LünemannJD, RíoJ, SánchezA, LópezC, JuliàE, FernándezM, NonellL, Camiña-TatoM, DeisenhammerF, CaballeroE, TortolaMT, PrinzM, MontalbanX, MartinR. 2009. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain, 132:3353–3365.
14.
CorvolJ-C, PelletierD, HenryRG, CaillerSJ, WangJ, PappasD, CasazzaS, OkudaDT, HauserSL, OksenbergJR, BaranziniSE. 2008. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. PNAS, 105:11830–11844.
15.
CrozeE, BeekmanJ, KnappertzV, SanbrinkR, PohlC, PazP, LindbergR, KapposL, ReischlJ. 2009a. Betaseron increases expression of metallothioneins in relapsing-remitting multiple sclerosis patients suggesting a role for betaseron in neuroprotection. Mult Scler, 15:S138.
16.
CrozeE, VelichkoS, TranT, YamaguchiKD, SalamonH, RederAT, KnappertzV, PazP. 2009b. Betaseron induces a novel alternative start transcript in cells obtained from relapsing-remitting multiple sclerosis patients and human brain that is associated with control of oxidative resistance. Mult Scler, 15:S138.
17.
CunninghamS, GrahamC, HutchinsonM, DrooganA, O'RourkeK, PattersonC, McDonnellG, HawkinsS, VandenbroeckK. 2005. Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther, 78:635–646.
18.
DerS, ZhouA, WilliamsB, SilvermanRH. 1998. Identification of genes differentially regulated by interferons α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA, 95:15623–15628.
19.
Dhib-JalbutS, MarksS. 2010. Interferon-β mechanisms of action in multiple sclerosis. Neurology, 74:S17–S24.
20.
FernaldGH, KnottS, PachnerA, CaillierSJ, NarayanK, OksenbergJR, MousaviP, BaranziniSE. 2007. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol, 178:5076–5085.
21.
FlorisS, RuulsSR, WierinckA, van der PolSM, DoppE, van der MeidePH, DijkstraCD, De VriesHE. 2002. Interferon-β directly influences monocyte inflitration into the central nervous system. J Neuroimmunol, 127:69–79.
22.
FujinamiRS, von HerrathM, ChristenU, WhittonJL. 2006. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Micro Rev, 19:80–94.
23.
GniadekP, OktasO, WandlingerK-P, Bellmann-StrobiJ, WengertO, WeberA, von WussowP, ObertH-J, ZippF. 2003. Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol, 137:187–196.
24.
GoertschesRH, HeckerM, ZerrlUK. 2008. Monitoring of multiple sclerosis immunotherapy from single candidates to biomarker networks. J Neurol, 255:48–57.
25.
GuoB, ChangEY, ChengG. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest, 118:1680–1690.
KurzkeJF. 1983. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology, 33:1444–1452.
37.
LallemandC, MeritetJF, EricksonR, GrossbergSE, RoulletE, Lyon-CaenO, LebonP, ToveyMG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res, 28:393–404.
38.
LeeNH. 2005. Genomic approaches for reconstructing gene networks. Pharmacogenomics, 6:245–258.
39.
LengyelP. 1982. Biochemistry of interferon and their actions. Ann Rev Biochem, 51:251–282.
40.
LeppertD, WaubantE. 1996. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol, 40:846–852.
41.
LinkovF, FerrisRL, YurkovetskyZ, MarrangoniA, VelikokhatnayaL, GoodingW, NolanB, WinansM, SiegelER, LokshinA, StackBC. 2008. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl, 10:1575–1585.
42.
Martin-SaavedraFM, Gonzalez-GarciaC, BravoB, BallesterS. 2008. β-interferon restricts the inflammatory potential of CD4 + cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol, 45:4008–4019.
43.
McDonaldWI, CompstonA, EdanG, GoodinD, HartungHP, LublinFD, McFarlandHF, PatyDW, PolmanCH, ReingoldSC, Sandberg-WollheimM, SibleyW, ThompsonA, van den NoortS, WeinshenkerBY, WolinskyJS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 50:121–127.
44.
MuraroPA, LiberatiL, BonanniL, PantalineCM, CaporaleC, IarloriG, DeLucaD, FarinaA, LugaresiD, GambiD. 2004. Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J Neuroimmunol, 150:123–131.
45.
O'SullivanLA, LiongueC, LewisRS, StephensonSE, WardAC. 2007. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol, 44:2497–2506.
46.
OwensT, BechmannI, EngelhardtB. 2008. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol, 12:1113–1121.
47.
PachnerAR, BertolottoA, DeisenhammerF. 2003. Measurement of MxA mRNA or protein as a biomarker of IFN beta bioactivity:detection of antibody-mediated decreased bioactivity (ADA)Neurology, 61:S24–S26.
48.
PenkowaM, HidalgoJ. 2003. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimential autoimmune encephalomyelitis. J Neurosci Res, 72:574–586.
RaniMR, XuY, LeeJC, ShrockJ, JosyulaA, SchlaakJ, ChakraborthyS, JaN, RansohoffRM, RudickRA. 2009. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci, 1182:58–68.
51.
RederAT, VelichkoS, YamaguchiKD, HamamciogluK, KuK, BeekmanJ, WagnerTC, PerezHD, SalamonH, CrozeE. 2008. IFN-β1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res, 28:317–331.
52.
RioJ, ComabellaM, MontalbanX. 2009. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol, 5:553–560.
53.
RobinsonWH, UtzP, SteinmanL. 2003. Genomic and proteomic analysis of multiple sclerosis. Curr Opin Immunol, 15:660–667.
54.
Russell-HardeD, WagnerTC, PerezHD, CrozeE. 1999. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun, 255:539–544.
55.
RuanY, Le BarP, NgHH, LiuET. 2004. Interrogating the transcriptome. Trends Biotech, 20:23–30.
56.
SatohJ, NanriY, TabunokiH, YamamuraT. 2006. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN-β-response genes in peripheral blood lymphocytes in vitro: an implication for IFN-β-related adverse effects in multiple sclerosis. BMC Neurol, 6:18–29.
57.
Serrano-FernandezP, MollerS, GoertschesR, FiedlerH, KoczanD, ThiesenHJ, ZettlUK. 2010. Time course transcriptomic of IFN-β1b drug therapy in multiple sclerosis. Autoimmunity, 43:172–178.
58.
ShariefMK, SemraYK. 2002. Down-regulation of survivin expression in T-lymphocytes after interferon-β1a treatment in patients with multiple sclerosis. Arch Neurol, 59:1115–1121.
59.
StarkGR, KerrIM, WilliamsBR, SilvermanRH, SchreiberRD. 1998. How cells respond to interferons. Annu Rev Biochem, 67:227–264.
60.
StürzebecherS, MaibauerR, HeunerA, BeckmannK, AufdembrinkeB. 1999. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res, 19:1257–1264.
61.
StürzebecherS, WandingerKP, RosenwaldA, SathyamoorthyM, TzouA, MattarP, FrankJA, StaudtL, MartinR, McFarlandHF. 2003. Expression profiling identifies responder and non-responder phenotypes to interferon beta in multiple sclerosis. Brain, 126:1419–1429.
62.
StüveO, ChabotS, JungSS, WilliamsG, YongVW. 1997. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol, 80:38–46.
63.
SubramanianA, TamayoP, MoothaVK, MukherjeeS, EbertBL, GilletteMA, PaulovichA, PomeroySL, GolubTR, LanderES, MesirovJP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102:15545–15550.
64.
The IFN beta Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43:655–661.
65.
TrojanoM, AvolioC. 1999. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology, 53:52–57.
66.
TzartosJS, FrieseMA, CranerMJ, PalaceJ, NewcombeJ, EsiriMM, FuggerL. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol, 172:146–155.
67.
VallittuAM, SarasteM, AirasL. 2007. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res, 29:763–766.
68.
Van BaarsenLG, VosslamberS, TijssenM, BaggenJM, van der VoortLF, KillesteinJ, van der Pouw KraanTC, PolmanCH, VerweijCL. 2008. Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS, 3:E1927.
69.
VosslamberS, van BaarsenL, VerweijCL. 2009. Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics, 10:97–108.
70.
WandingerKP, StürzebecherCS, BielekovaB, DetoreG, RosenwaldA, StaudtLM, McFarlandHF, MartinR. 2001. Complex immunomodulatory effects of interferon beta in multiple sclerosis including the upregulation of T helper 1-associated marker genes. Ann Neurol, 59:349–357.
71.
WangZ, GersteinM, SnyderM. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet, 10:57–63.
72.
WaubantE, GeeL, BacchettiP, SloanR, CotleurA, RudickR, GoodkinD. 2001. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol, 112:139–145.
73.
WeinerHL. 2009. The challenge of multiple sclerosis: how do we cure a chronic heterogenous disease?Ann Neurol, 65:239–248.
Weinstock-GuttmanB, RansohoffRM, KinkelP, RudickRA. 1995. The interferons: biologic effects, mechanism of action, and use in multiple sclerosis. Ann Neurol, 37:7–15.
76.
WillsRJ. 1990. Clinical pharmacokinetics of interferons. Clin Pharmacokinet, 19:390–399.
77.
YamaguchiKD, RudermanDL, CrozeE, WagnerTC, VelichkoS, RederAT, SalamonH. 2008. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neurol, 195:116–120.
